LabPro Connect

Join Dr. Ahmed Babiker, Assistant Professor, Rush University, and Professor Elaine Cloutman-Green, Principal Clinical Scientist in Infection Control at Great Ormond Street Hospital for Children, London as they explore the evolution of superbugs and superbugs’ impact to clinical treatment. They will present case study examples, and discuss global infection prevention strategies to support antibiotic stewardship.

Key learning objectives

• Explore the evolution of superbugs and current top priority global threats
• Recognize the impact, and outcome, of resistant bacteria present in the clinical setting
• Explore key infection prevention strategies

Who should attend?

• Clinical microbiology lab directors/supervisors/managers
• Microbiologists
• Microbiologist lab technicians
• Infectious disease specialists
• Infectious disease pharmacists
• Clinical microbiology lab executives
• Antibiotic stewardship committee members

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Over the past five years, healthcare systems have faced a troubling rise in Gram-negative multidrug-resistant organisms (MDROs), contributing to increased patient morbidity and mortality. At the forefront of this surge are NDM-CREs (New Delhi metallo-β-lactamase-producing carbapenem-resistant Enterobacterales), which have skyrocketed by 460% between 2019 and 2023, according to a recent report from the Centers for Disease Control and Prevention (CDC)1. Another report by the European Centre for Disease Control (ECDC) showed a 57% increase in bloodstream infections caused by carbapenem resistant bacteria in the same time period2.

These alarming trends underscore the urgent need for robust screening protocols and precise antibiotic susceptibility testing, especially for high-risk patient populations.

Join our group of industry experts for an insightful case-based webinar exploring the complex patient journey of a 76-year-old woman residing in a nursing home. Her story begins with a fall leading to an emergency room visit where she is found to have a hip fracture. She is admitted and has an uneventful surgical repair the next day but develops urosepsis during her post-op recovery.

This case highlights the heightened vulnerability of elderly patients to MDROs, particularly CREs. Through this patient’s journey, the speakers will examine the critical role of infection prevention protocols and the value of accurate diagnostic and antibiotic susceptibility testing in guiding effective treatment as they are applied throughout a healthcare system.

The session will also incorporate the latest IDSA guidelines for managing complicated urinary tract infections, including urosepsis, offering practical insights for clinicians, microbiologists, and infection control professionals.

Key learning objectives:

• Describe how rapid PCR screening plays a critical role in enhancing infection control protocols to help minimize transmission and support timely patient management.
• Explain how rapid AST results support optimal antimicrobial therapy decision-making to help improve patient outcomes and combat resistance.
• Outline the latest IDSA guidelines for complicated urinary tract infections.
• Discuss the impact of antimicrobial resistance and diagnostic stewardship in real-world settings.

Who should attend?

Clinical microbiology lab directors/supervisors/managers, microbiologists, microbiologist lab technicians, infectious disease specialists, infectious disease pharmacists, clinical microbiology lab executives, antibiotic stewardship committee members, infection preventionists

Accreditation statement

SelectScience® is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.

References:
1. CDC Report Finds Sharp Rise in Dangerous Drug-Resistant Bacteria | CDC Newsroom
2. Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report 2023

Phenotypic antimicrobial susceptibility testing is the gold standard test for treatment decisions, but emerging antimicrobial resistance and new antimicrobials for Gram-negative bacterial infections are challenging the conventional wisdom that a minimum inhibitory concentration (MIC) is all that is needed. Asking the question, "How can we meet evolving diagnostic needs?", we hear from three key microbiology and infectious disease experts: Prof. Navaneeth Narayanan, Rutgers University Ernest Mario School of Pharmacy, Prof. Amy Mathers, University of Virginia, School of Medicine, and Dr. April Abbott, Deaconess Health System, in this educational webinar.

Key learning objectives

• Discover the new drugs available for treating MDRO Gram-negative infections
• Understand the challenges and opportunities associated with MDRO Gram-negative diagnostics

Who should attend?

• Clinical microbiology lab directors/supervisors/managers
• Microbiologists
• Microbiologist lab technicians
• Infectious disease specialists
• Infectious disease pharmacists
• Clinical microbiology lab executives
• Antibiotic stewardship committee members

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.